<SEC-DOCUMENT>0001193125-16-638222.txt : 20160630
<SEC-HEADER>0001193125-16-638222.hdr.sgml : 20160630
<ACCEPTANCE-DATETIME>20160630160603
ACCESSION NUMBER:		0001193125-16-638222
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20160630
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160630
DATE AS OF CHANGE:		20160630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		161743191

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d217819d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): June&nbsp;30, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dublin 2, Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of Chief Financial Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;30, 2016, Amarin Corporation plc (the &#147;Company&#148;) issued a press release announcing that it has named Michael Kalb as its Senior Vice President and Chief Financial Officer, effective immediately. Mr.&nbsp;Kalb will act as the
Company&#146;s principal financial officer and principal accounting officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Kalb served as Group Vice President, Chief Financial Officer and
Chief Accounting Officer of Taro Pharmaceutical Industries Ltd. (&#147;<U>Taro</U>&#148;) from August 2014 to June 2016. Prior to that, Mr. Kalb was Interim CFO from November 2010 to August 2014 and GVP, Interim CFO and CAO from May 2010 to June
2016. Mr. Kalb joined Taro in June 2009 as VP, Chief Financial Officer &#150; U.S. He has over twenty years of financial and accounting advisory experience. From June 2004 to June 2009, Mr.&nbsp;Kalb served as a Director in the Accounting and
Financial Consulting Group of Huron Consulting Group Inc. His experience also includes over ten years at Ernst&nbsp;&amp; Young, LLP within the Transaction Advisory Services Group and Audit and Assurance Services Group. Mr.&nbsp;Kalb received a
Bachelor of Science in Accounting from the University at Albany, State University of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2016, in connection with
Mr.&nbsp;Kalb&#146;s appointment, the Company entered into an employment agreement with Michael Kalb (the &#147;Kalb Agreement&#148;). Pursuant to the Kalb Agreement, Mr.&nbsp;Kalb will report to the Company&#146;s Chief Executive Officer, and his
initial base annual salary will be $400,000. Mr.&nbsp;Kalb will also receive a one-time special bonus of $25,000, and going forward he will be eligible to receive an annual performance bonus targeted at 40% of his base salary, with the actual amount
of such bonus, if any, to be determined by the Board of Directors. Mr.&nbsp;Kalb will also be entitled to continue to participate in the benefits and insurance programs generally available to all Company employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his hiring, Mr.&nbsp;Kalb will receive nonqualified options to purchase 625,000 shares of the Company&#146;s ordinary shares represented by
American Depositary Shares with a ten-year term and an exercise price equal to the closing price of the Company&#146;s American Depositary Shares on the NASDAQ Global Market on the date of grant. Twenty-five percent of the options vest on the first
anniversary of the grant date with the remaining seventy-five percent to vest ratably over the subsequent thirty-six-month period, subject to Mr.&nbsp;Kalb&#146;s continued employment with the Company over such period. The grant was approved by the
Remuneration Committee of the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kalb Agreement provides further that, if Mr.&nbsp;Kalb is terminated without cause,
he will be entitled to severance as follows: continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA; six (6)&nbsp;months of
accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. If Mr.&nbsp;Kalb is terminated without cause or he quits for good reason, in either case, within the twenty-four (24)&nbsp;months following a
change in control, then he will be entitled to severance as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent
with COBRA; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of vesting on all outstanding equity inventive awards. All references to
&#147;cause,&#148; &#147;good reason&#148; and &#147;change in control&#148; are as defined in the Kalb Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Kalb
Agreement is qualified in its entirety by reference to the complete text of the Kalb Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the press release
announcing Mr.&nbsp;Kalb&#146;s appointment is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships between Mr.&nbsp;Kalb with any other executive officers of the Company or members of the Board of Directors, and he has no
direct or indirect material interest in any transaction required to be disclosed pursuant to Item&nbsp;404(a) of Regulation S-K. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2016, the Company issued a press release announcing the appointment of
Mr.&nbsp;Kalb as Senior Vice President and Chief Financial Officer. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement with Mr. Michael Kalb, dated May 9, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June 30, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: June&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement with Mr. Michael Kalb, dated May 9, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June 30, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d217819dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;9, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Michael&nbsp;W. Kalb </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 Lucille Lane </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dix Hills, New York 11746 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mike: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Amarin Corporation plc (the &#147;Company&#148;), I am pleased to offer you employment in the role the Company&#146;s Senior Vice
President and Chief Financial Officer under the following terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Position:</B> Senior Vice President and Chief Financial Officer is
a full-time position as an officer of the Company. It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time).
Notwithstanding the foregoing, you may engage in religious, charitable, or other community activities so long as such services or activities do not interfere or conflict with your obligations to the Company. In addition to your role as Senior Vice
President of the Company, you acknowledge and agree that you may be required, without additional compensation, to perform duties for certain affiliated entities of the Company, including without limitation Amarin Pharma, Inc., and to accept any
reasonable office or position with any such affiliate as the Company&#146;s Board of Directors may require, including, but not limited to, service as an officer or director of any such affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Work Location: </B>Your principal place of employment will be the Company&#146;s offices which are currently located in Bedminster, New
Jersey, subject to business travel requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Start Date</B>: Unless otherwise agreed, your first day of employment will be
July&nbsp;5, 2016, or such earlier date as may be mutually determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Salary:</B> The Company will pay you a salary at the annual
rate of $400,000 subject to periodic review and adjustment at the discretion of the Company. Currently our policy is to make salary payments semi-monthly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Bonuses:</B> You will be eligible to receive annual performance bonuses. The Company will target the bonus of up to 40% of your salary
for the year. The actual bonus is discretionary and will be subject to the Company&#146;s assessment of your performance, as well as business conditions at the Company. The bonus also will be subject to your employment for the full period covered by
the bonus, approval by and adjustment at the discretion of the Company&#146;s Board of Directors or an authorized committee thereof, and the terms of any applicable bonus plan. The Company may also make adjustments in the targeted amount of your
annual performance bonus. Any bonus awarded to you will be paid by March&nbsp;15 of the year following the bonus year to which such bonus relates. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Special Bonus: </B>On September15, 2016, you will receive a lump sum bonus of $25,000
(less applicable withholdings and deductions) . In order to not forfeit this special bonus, you must not resign your employment or be terminated for cause prior to July&nbsp;5, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Benefits:</B> You will be eligible to participate in the employee benefits and insurance programs generally made available to the
Company&#146;s full-time employees, including health, life, disability and dental insurance. You will be eligible for up to 18 days of paid time off or such other amount determined by the Company, which shall accrue and in other respects be
administered in accordance with the Company&#146;s policy from time to time. You will be reimbursed for all reasonable business expenses you incur while carrying out your duties on behalf of the Company; provided such reimbursement shall be
conditioned on you following the Company&#146;s reimbursement policies and claims procedure, including by providing reasonable documentation of such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B>Stock Options:</B> You will be eligible to participate in the Company&#146;s stock option program, subject to approval by the Board of
Directors. After you join the Company, we will recommend the grant to you of an option to purchase 625,000 ordinary shares of the Company. Under current Company policy, the exercise price of your stock option will be equal to the closing price of
the Company&#146;s American Depository Shares (ADS) on The NASDAQ Stock Market at the close of the first trading day of the month following your Start Date. Vesting of such stock option will be scheduled over a four year period with 25% vesting
after one year after your Start Date and the balance vesting monthly over the subsequent thirty-six months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B>Equity: </B>The terms
and conditions of your equity awards shall be set forth in a stock option and/or restricted stock agreements, as applicable, that are expected to substantially reflect the various terms and conditions of the Company&#146;s 2011 Stock Incentive Plan
as may be amended from time to time (collectively the &#147;Equity Documents&#148;) provided, and notwithstanding anything to the contrary in the Equity Documents, Section&nbsp;8 of this Agreement shall control with respect to any of your equity
interests that are unvested as of the Date of Termination, provided further, nothing herein shall be construed to be less favorable to you than the terms of the Equity Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B>At-will Employment, Accrued Obligations; Severance:</B> Your employment is &#147;at will&#148; meaning you or the Company may terminate
it at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the Accrued Obligations, defined as (1)&nbsp;your base salary through the date of termination, (2)&nbsp;an amount equal
to the value of your accrued unused paid time off days, if any, and (3)&nbsp;the amount of any business expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed, if any, within ten
(10)&nbsp;days of the last day of your employment (&#147;Date of Termination&#148;). In addition to the Accrued Obligations, in the event the Company terminates your employment without Cause at any time, or during the twenty-four (24)&nbsp;month
period that immediately follows a Change of Control (the &#147;Post-Change in Control </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Period&#148;) the Company terminates your employment without Cause or you terminate your employment for Good Reason (defined below), the Company shall provide you with the following termination
benefits (the &#147;Termination Benefits&#148;), depending on the Date of Termination: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">continuation of your base salary then in effect during the &#147;Salary Continuation Period&#148; which shall be either: (A)&nbsp;six (6)&nbsp;months from the Date of Termination, if the Company terminates your
employment without Cause and the Date of Termination occurs at any time outside of the Post-Change in Control Period, or (B)&nbsp;twelve (12)&nbsp;months from the Date of Termination, if the Company terminates your employment without Cause or you
terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the Post-Change in Control Period. Solely for purposes of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, each Salary
Continuation Payment during the Salary Continuation Period is considered a separate payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#147;COBRA&#148;), with the cost of the regular premium for such benefits
shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of: (i)&nbsp;the end of the Salary Continuation Period, and (ii)&nbsp;the date you become eligible for health benefits through
another employer or otherwise become ineligible for COBRA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the Post-Change in Control Period, a lump sum cash
payment equal to your target annual performance bonus for the year during which the Date of Termination occurs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">if the Company terminates your employment without Cause and the Date of Termination occurs outside of the Post-Change in Control Period, six (6)&nbsp;months of accelerated vesting from the Date of Termination with
respect to any of your then outstanding stock options, restricted stock units or other equity incentive awards (in each case, only to the extent subject to time-based vesting); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the Post-Change in Control Period, then outstanding
stock options, restricted stock units or other equity incentive awards (whether or not subject to time based vesting) shall immediately vest in full effective upon the Date of Termination. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination
Benefits unless you first (i)&nbsp;enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company which shall include a release of claims against the Company and related persons and entities (the
&#147;Release&#148;), provided that the Release shall not require you to release (a)&nbsp;claims to enforce your right to receive Termination Benefits; (b)&nbsp;claims for vested benefits pursuant to ERISA; (c)&nbsp;claims with respect to your
vested equity rights as of the Date of Termination; (d)&nbsp;claims to enforce the Company&#146;s obligation to indemnify you to the extent such indemnification obligations exist; and (e)&nbsp;claims which legally may not be waived; (ii)&nbsp;resign
from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii)&nbsp;return all Company property and comply with any
instructions related to deleting and purging duplicates of such Company property, in each case within the time period designated by the Company but in no event later than 60 days of the Date of Termination. The Salary Continuation Payments shall
commence within 60 days after the Date of Termination and shall be made on the Company&#146;s regular payroll dates; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation
Payments shall begin to be paid in the second calendar year. In the event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment, the first Salary Continuation Payment shall include a &#147;catch
up&#148; payment. Notwithstanding the foregoing, if you breach any of the material provisions of this Agreement or the Nondisclosure Developments and Non-competition Agreement, in addition to all other rights and remedies, the Company shall have the
right to terminate or cease payment of the Termination Benefits. For the avoidance of doubt, you shall not be entitled to the Termination Benefits in the event your employment ends due to your death or disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B>Definitions: </B>For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; shall mean: (i)&nbsp;conduct by you constituting an act of material misconduct in connection with the performance of your duties, including,
without limitation, misappropriation of funds or property of the Company other than the occasional, customary and de minimis use of Company property for personal purposes; (ii)&nbsp;the commission by you of (A)&nbsp;any felony; or (B)&nbsp;a
misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any conduct by you that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates if you
were retained; (iv)&nbsp;continued non-performance or continued unsatisfactory performance by you of your responsibilities as reasonably determined by the Company&#146;s Board of Directors; (v)&nbsp;a breach by you of any of the material provisions
of any agreement between you and the Company including, without limitation, any agreement relating to non-disclosure, non-competition or assignment of inventions; (vi)&nbsp;a material violation by you of any of the Company&#146;s written policies or
procedures provided that, other than in the case of noncurable events, you are provided with written notice and fifteen (15)&nbsp;days to cure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
meaning of &#147;Change of Control&#148; shall be limited to the following events, but only to the extent such events constitute a &#147;change in the ownership or effective control&#148; of the Company or a &#147;change in the ownership of a
substantial portion of the Company&#146;s assets&#148; for purposes of Section&nbsp;409A of the Code: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">any person or company (either alone or together with any person or company acting in concert with him or it) (an &#147;Acquiring Company&#148;) obtaining Control of the Company, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">any person or company that Controls the Company becoming bound or entitled to acquire Shares under sections 974 to 991 of the UK Companies Act 2006, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">any court sanctioning a compromise or arrangement under section 899 of the UK Companies Act 2006, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">a resolution being tabled for the voluntary winding-up of the Company, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">any Acquiring Company acquiring all or substantially all of the assets of the Company, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">any merger, reorganization, consolidation or other similar transaction pursuant to which the holders of the Company&#146;s outstanding voting power and outstanding stock immediately prior to such transaction do not own
a majority of the outstanding voting power and outstanding stock or other equity interests of the Company or any resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction,
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">the sale of all or a majority of the Shares of the Company to an unrelated person, entity or group thereof acting in concert, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">any other similar transaction which the Board determines should constitute a Change of Control for the purposes of the Plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Control&#148; means the ownership of more than fifty (50)&nbsp;percent of the issued share capital or other equity interest of the Company or the legal
power to direct or cause the direction of the general management and policies of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Good Reason&#148; shall mean that you have complied
with &#147;Good Reason Process&#148; (hereinafter defined) following the occurrence of any of the following Good Reason conditions that occur without your consent: (i)&nbsp;a material diminution of your base salary; (ii)&nbsp;a material diminution
in your authority, duties or responsibilities; (iii)&nbsp;a material change in the principal location where you are required to provide services for the Company (not including business travel and short-term assignments); and/or (iv)&nbsp;a material
breach by the Company of this Agreement. For purposes of this Agreement, &#147;Good Reason Process&#148; shall mean that: (x)&nbsp;you reasonably determine in good faith that a &#147;Good Reason&#148; condition has occurred; (y)&nbsp;you notify the
Company in writing of the Good Reason condition within thirty&nbsp;(30) days of the first occurrence of such condition; (z)&nbsp;you cooperate in good faith with the Company&#146;s efforts, for a period of
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thirty (30)&nbsp;days following such notice (the &#147;Cure Period&#148;), to remedy the condition; notwithstanding such efforts, the Good Reason condition continues to exist; and you terminate
your employment within thirty (30)&nbsp;days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B>Section&nbsp;280G Limitation:</B> Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of you, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G
of the Code and the applicable regulations thereunder (the &#147;Severance Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, the following provisions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If the Severance Payments, reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and
local income and employment taxes payable by you on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, you shall be entitled to the full benefits payable under this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Threshold Amount is less than (x)&nbsp;the Severance Payments, but greater than (y)&nbsp;the
Severance Payments reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the
Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order:
(1)&nbsp;cash payments not subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and (4)&nbsp;non-cash forms of benefits. To the extent any payment
is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Section, &#147;Threshold Amount&#148; shall mean three times your &#147;base amount&#148; within
the meaning of Section&nbsp;280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and &#147;Excise Tax&#148; shall mean the excise tax imposed by Section&nbsp;4999 of the Code, and any interest or penalties
incurred by you with respect to such excise tax. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The determination as to which of the alternative provisions of this
Section&nbsp;9 shall apply to you shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and you within 15 business
days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or you. For purposes of determining which of the alternative provisions of this Section&nbsp;9 shall apply, you shall be deemed to pay
federal income taxes at the highest </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates
of individual taxation in the state and locality of your residence on the date of termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the
Accounting Firm shall be binding upon the Company and you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B>Taxes; Section&nbsp;409A:</B> All forms of compensation referred to in
this letter agreement are subject to reduction to reflect applicable withholdings and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner
that minimizes tax liabilities. Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&nbsp;409A of the Code, the Company determines that you are a &#147;specified
employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred
compensation subject to the 20 percent additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be
provided until the date that is the earlier of (A)&nbsp;six months and one day after your separation from service, or (B)&nbsp;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include
a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time
periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was
incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to
reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any payment or benefit described in
this Agreement constitutes &#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of this Agreement, then such payments or benefits shall be
payable only upon your &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties intend that this Agreement will be administered in accordance with
Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with
Section&nbsp;409A of the Code. The parties agree that this Agreement may be </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the
payments and benefits provided hereunder without additional cost to either party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company makes no representation or warranty and shall have no
liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B>Representation Regarding Other Obligations: </B>This offer is conditioned on your representation that you are not subject to any
confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company. If you have entered into any agreement that may restrict your activities
on behalf of the Company, please provide me with a copy of the agreement as soon as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B>Other Terms:</B> Your employment
with the Company shall be on an at-will basis. In other words, you or the Company may terminate employment for any reason and at any time, with or without notice, subject to the Termination Benefits provisions herein. Similarly, the terms of
employment outlined in this letter are subject to change at any time. If you have not already done so, you also will be required to sign the Company&#146;s Nondisclosure Developments and Non-competition Agreement as a condition of this letter
agreement and your continued employment, the terms of which shall be incorporated by reference into this letter agreement. A copy of that letter agreement is enclosed. In addition, this letter agreement is contingent on the completion of references
checks and a background investigation that are satisfactory to the Company (as determined by the Company) and your submission of satisfactory proof of your identity and your legal authorization to work in the United States and a satisfactory
Company-paid initial-employment physical and drug screen, in each case to the extent not already completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B>Interpretation,
Amendment and Enforcement:</B> This Agreement, including the Company&#146;s Nondisclosure Developments and Non-competition Agreement and the Equity Documents, constitute the complete agreement between you and the Company, contain all of the terms of
your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning,
effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;Disputes&#148;) will be
governed by the laws of the State of New Jersey, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of New Jersey in
connection with any Dispute or any claim related to any Dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <B>Assignment: </B>Neither you nor the Company may make any
assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g69p26.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to one of its Affiliates or to any person with whom the
Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and
each of our respective successors, executors, administrators, heirs and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are excited about the opportunity to work
with you at Amarin. If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer of employment by signing below and returning a copy to me. We are confident that with your
background and skills, you will have an immediate positive impact on our organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed for and on behalf of: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMARIN&nbsp;CORPORATION&nbsp;PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;/s/ John Thero</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dated:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ACCEPTED:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Signed:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;/s/ Michael W. Kalb</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Name:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I></I>Michael W. Kalb</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dated:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B></B>May&nbsp;11, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d217819dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g217819g78e20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Appoints Michael W. Kalb Chief Financial Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, June&nbsp;30, 2016 &#151; Amarin Corporation plc (NASDAQ: AMRN) announced that starting today Michael W. Kalb has
joined its senior management team as senior vice president and chief financial officer. A seasoned financial executive, Mr.&nbsp;Kalb brings over 20 years of international financial operations and accounting advisory experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to welcome Mike to our team and look forward to leveraging his extensive experience and leadership capabilities as we continue to grow
our commercial business and work toward the completion of our cardiovascular outcomes study,&#148; commented John F. Thero, president and chief executive officer of Amarin. &#147;Mike&#146;s broad, global business and pharmaceutical experience will
further strengthen our executive, financial and operational capabilities as we continue our commercial growth and work toward expanding our business in the future.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Kalb joins Amarin from Taro Pharmaceutical Industries, Ltd., a publicly-traded, multinational, science-based pharmaceutical company where he served
as chief financial officer and chief accounting officer. Prior to joining Taro, Mr.&nbsp;Kalb was a director in the Accounting and Financial Consulting Group of Huron Consulting Group Inc. Mr.&nbsp;Kalb&#146;s experience also includes over ten years
at Ernst&nbsp;&amp; Young, LLP within its Transaction Advisory Services Group and Audit and Assurance Services Group. He is a certified public accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Kalb added, &#147;I am very happy to become a part of the Amarin team. The company has made great progress recently in increasing awareness of
Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and its clinical profile. I am excited both by Vascepa&#146;s revenue growth and its large potential upside and look forward to working with the Amarin team to help build upon the
company&#146;s success and drive shareholder value.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin&#146;s clinical program includes a commitment to an ongoing outcomes study.
Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), Amarin&#146;s first FDA-approved product, is a highly pure omega-3 fatty acid product available by prescription. For more information about Vascepa, visit
www.vascepa.com. For more information about Amarin, visit www.amarincorp.com. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about Amarin&#146;s commercial development and research programs and the
anticipated contribution of executives to Amarin&#146;s progress. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S.
Securities and Exchange Commission, Amarin&#146;s ability to effectively commercialize Vascepa will depend in part on its ability to continue to effectively finance its development programs, create market demand for Vascepa through education,
marketing and sales activities, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent
protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: individual contributions to Amarin from the named executives, uncertainties associated
generally with research and development, clinical trials and related regulatory approvals; the risk that related cost may increase beyond expectations; the risk that Vascepa may not show clinically meaningful effects in REDUCE-IT or support
regulatory approvals for cardiovascular risk reduction; and the risk that Amarin&#146;s patent applications and patents may not be sufficient to protect the company from generic competition. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information about Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations
website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs,&nbsp;Securities and Exchange Commission&nbsp;filings, press releases, public conference calls and webcasts. The
information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including
our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website
that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations:
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathryn McNeil</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1
(908) 719-1315 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com </U></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout
Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646)&nbsp;378-2992 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristie Kuhl </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finn Partners </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (212)&nbsp;583-2791 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kristie.kuhl@finnpartners.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g217819g69p26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g217819g69p26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !% 4\# 2(  A$! Q$!_\0
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MBB@ K\Y?^"S'_!;.S_8\TVZ^'?PMU&RU#XJS86\O!&ES;^%TZ_.K H]P>T;
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M5.*]R6L?3M\MCV^%\X_M' 1J2?OQTEZKK\]PHHHKP#Z,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BFF15/) _&CSE_O+^= #J*;YR_WE_.L#XJ?%'1?@U\-=>\6:_>
M1V>B^'+";4;V9F'R11(7;'J<# '<D#O3C%R:C'=DRDHIRD]$?G)_P7S^-FL_
M'/QY\-?V3_ <Y?Q%\1]2M[S7/+.1;VHD_<I)CHNY7G;/\-NIZ&OS[_X+4_\
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M.'_!QY^RXPR/$GB@C_L7;G_XFON:_P!+MM5A,=U;07,9!!66,."#[&OY[/\
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M'). >!7Q"W_!QS^R]&P#>(?%:,1G:_ANZ4_EMK[L(W#!K\]O^#D?X;Z!??\
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MTW\$?VG?AY^TGH[7W@+QIX;\6VZ#=)_9E_'.\(_VT!W)_P " KYQ_P""B?\
MP1F^%?[9_P ,]6GT?PWH_A#XBPV[RZ5K>EVR6OG3@$K'<H@"RQN>"6&Y<Y!X
MP?YV?"?B_P 4? +XDC4M"U75?"OBG0+IHQ=6%PUO<6LT;%67<I'1@00>#W%<
MN6\/9?FE&4L'.4)QW4K/TV2T_JQUYIQ+F.45XQQT(SA+9QNGY[MZK^F?UW5X
M+^VC_P %)/A;^P+=Z!#\1K[6;)O$B3R61LM*FO%80E ^XQ@A?]8N,]>?2O&?
M^"(7_!3N^_X*"_!#4],\7?9Q\1/ YBAU.6%!&FJV\@;RKL(.%8E&5U' 8 C
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M>+:ZI.S^^S_(_2ZWM)TG["23>S:NONNOS/AE?^#CS]EQAD>)/%!'J/#MS_\
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MC_O5[3_P3*_X*+Z/^T#_ ,$WK;XD>*]3B@U#X?Z?+9^+I78;HY;2+<TQ&?\
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M-2WB+Y>**4 !U1FP!@$ KQW.C_P3<_;3U#]@O]K7PYX[@::31@_V#7[2,_\
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M4JM453VJD^;>]];][C=&FZ?LG%<NUK:6[6/!%_X(/_LGHN!\(M/ ]!J^H_\
MR12_\.(OV4/^B1V'_@XU'_Y(HHKM_MC'_P#/^?\ X%+_ #.+^QLO_P"?$/\
MP&/^0B_\$(/V3UZ?"+3Q]-7U'_Y(HD_X(._LG2KAOA#IS#WU?4?_ )(HHH_M
MC'_\_P"?_@4O\P_L;+_^?$/_  &/^1]0_#CX=Z-\(_ .C>%_#MBFFZ#X?LXM
M/T^T1V=;:"-0J("Q+'"@#))/O6RPW+@]#Q117GN3D^9[GHQBHKECL?)%S_P0
ME_91N[V6XD^$6G&:=VD=AJVH#<S')/$_J:;_ ,.(OV4/^B1V'_@XU'_Y(HHK
MT/[7Q_\ S_G_ .!/_,\[^QLO>]"'_@,?\@/_  0@_9/88/PBT\C_ +"^H_\
MR134_P""#G[)T7W?A!IR_35]1_\ DBBBC^V,?_S_ )_^!2_S#^QLO_Y\0_\
M 8_Y#O\ AQ%^RA_T2.P_\'&H_P#R14EC_P $*_V4].U*WNX?A'IRW%K(LT3G
M5M0.QE(8'F?U HHH_M?'_P#/^?\ X$_\P639>MJ$/_ 8_P"1];#@5Y7^U'^Q
M+\+?VTM(TJQ^)OA&R\4P:',\]AYL\T#VS. K[7B=&PP R"<':#C(%%%<5*K.
ME)3IMIKJM&=U6E3JP=.K%23Z-71XS_PXB_90_P"B1V'_ (.-1_\ DBFO_P $
M&OV39&R?A!II/J=6U'_Y(HHKM_MC'_\ /^?_ (%+_,X?[&R]?\N(?^ Q_P A
MP_X(0_LH ?\ )(K#_P '&H__ "10?^"$/[*!'_)(M/\ _!QJ/_R1111_;&/_
M .?\_P#P*7^8?V-E_P#SXA_X#'_(8/\ @@Q^R6/^:/Z9_P"#;4?_ )(I_P#P
MXB_90_Z)'8?^#C4?_DBBBC^V,?\ \_Y_^!2_S#^QLO>]"'_@,?\ (ZKX'_\
M!(W]G?\ 9O\ BGI?C;P7\-K'0_%&BL[65^FHWLK0%XVC;"R3,IRCL.0>M?2%
M%%<E?$UJ\N:M)R?FV_S.NAAJ-"/)1@HKR27Y!1116)N?+_[1O_!(OX1_M*_M
M.>&/B[J,6NZ#XS\-7MM?O/HMQ#!%K$EO(DD7VM'BDW[=@7<A1BIP6.%Q]044
=5O5Q5:K&,*DFU'1>2.>CA*-&<ITHI.3N[=6?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g217819g78e20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g217819g78e20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  _ 2D# 2(  A$! Q$!_\0
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M_P %%O!VN_M)_LYZA^V#XR6ZM]6^-7Q(FTSPS9RN=MIHEK;2JF%Z$;D1 ?\
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M)_X*A:AJVI:O=16EE;?\(9I"R7$TC!41=UN,[F(&/4U]N?\ !0_]ABT_;O\
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M?PEI\?[5OCGQ=\//"I*+X2U'P[9BWN(-K!8!<%FFC1200%/&T 8%?;$]BMU
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(%QI1B][(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
